Vulvovaginal Candidiasis Treatment Market Size, Share & Industry Trends Analysis Report By Distribution Channel, By Route of Administration (Oral, Intravenous and Topical), By Drug Class, By Regional Outlook and Forecast, 2022

The Global Vulvovaginal Candidiasis Treatment Market size is expected to reach $1.3 billion by 2028, rising at a market growth of 4.6% CAGR during the forecast period.

Vulvovaginal Candidiasis is generally caused due to candida Albicans or candida species or yeast. Some of the symptoms of vulvovaginal candidiasis include abnormal vaginal discharge, vaginal soreness, dyspareunia, external dysuria, and pruritis. As per the data provided by the Centers for Disease Control and Prevention, around 75% of women are predicted to have vulvovaginal candidiasis at least one time and 40%-45% of women may have the condition two or more times. The condition is classified as complicated or uncomplicated on the basis of clinical presentation, host factors, microbiology, and response to therapy.

The condition generally rises the need to consider a gynecologist or nurse practitioner. Vulvovaginal Candidiasis can be diagnosed and managed by antifungal medications. Although vulvovaginal candidiasis could be treated in a few days, in cases of complicated situations the treatment could be for a longer period.

Patient awareness is very crucial in this condition. Though vulvovaginal candidiasis is not life-threatening it is essential to have adequate medication over time as it may become worse and lead to withdrawal from sexual activities out of embarrassment. Malignancy, abuse, trauma, inflammatory bowel disease, sexual transmission of infections, and immune disease could be some of the reasons for vaginal discomfort. The patients must undergo a complete and careful physical test, and proper ancillary testing to know about the exact reason for the condition for further treatment.

One should undergo the diagnosis of vulvovaginal candidiasis if the person feels pain, redness, or swelling in the vaginal area. The condition of vulvovaginal candidiasis is linked to normal vaginal pH which is 4.5. Using 10% of KOH in wet preparations helps in improving the visualization of mycelia and yeast via disrupting cellular material which may hide the pseudohyphae or yeast. It is important for all women having symptoms of vulvovaginal candidiasis to undergo an examination of the wet mount with KOH preparation and get treatment on time.

COVID-19 Impact Analysis

The widespread novel coronavirus all over the world has slightly impacted the growth of the vulvovaginal candidiasis treatment market. The demand for drugs for vulvovaginal candidiasis was high due to the rising prevalence of candidiasis among patients who have suffered from COVID-19. This is because of the rise in healthcare-associated infections and bloodstream infections, especially among those who were admitted to hospitals. Owing to all these elements, the vulvovaginal candidiasis market has quickly recovered after the first quarter of 2020 and is further anticipated to continue to grow.

Market Growth Factors

Growing spending on research & development and expansion of product portfolio

The market has been witnessing the introduction of various safe & effective antifungal agents. Some of the effective antifungal agents available in the market are terbinafine, fluconazole, and itraconazole. The pharmaceutical industries are increasing the expenditure on research & development intending to expand their product portfolio for anti-infective drugs. Most of the market players are focusing on the development of effective therapeutic agents for patients with weak immunity systems to cure fungal infections such as vulvovaginal candidiasis.

Rising prevalence of diabetes

The prevalence of diabetes is growing continuously all over the world. According to the data provided by WHO, in 1980, patients with diabetes was around 108 million, which rose to 422 million in 2014. The prevalence has been growing more rapidly in low-income and middle-income nations as compared to high-income nations. Diabetes is one of the reasons for various serious issues such as stroke, heart failure, blindness, kidney failure, and others. In 2014, about 8.5% of adults above the age of 18 were diabetic. As the prevalence of diabetes across the world is growing, the cases of vulvovaginal candidiasis are also predicted to increase. This would result in market growth for the vulvovaginal candidiasis treatment in the upcoming years.

Market Restraining Factor

Side effects of consumption of medicines such as fluconazole

Medicines such as fluconazole are antifungal medications prescribed to cure candida fungal infections such as vulvovaginal candidiasis. The consumption of fluconazole may lead to drug interaction with various blood thinners, antibiotics, sedatives, diuretics, antiseizure, and various other medications. Also, various cautions mentioned on the medicines are applied to individuals having liver disorders or any other diseases which could lead to the side effect of consuming such conditions.

Distribution Channel Outlook

On the basis of distribution channel, the vulvovaginal candidiasis treatment market is divided into hospital pharmacy, retail pharmacy and online pharmacy. In 2021, the retail pharmacy segment witnessed the highest revenue share in the vulvovaginal candidiasis treatment market. The disease treatment takes short as well as long-term support of medications which raises the sale of treatment drugs from retail pharmacies.

Route of Administration Outlook

By route of administration, the vulvovaginal candidiasis treatment market is fragmented into oral, intravenous and topical. The topical segment covered a significant revenue share in the vulvovaginal candidiasis treatment market in 2021. This is attributable to the availability of topical products such as prescription formulations and over-the-counter. Topical OTCs include Miconazole cream, Tioconazole ointment, and Clotrimazole cream and prescription formulations include Terconazole cream and Butoconazole cream.

Drug Class Outlook

Based on drug class, the vulvovaginal candidiasis treatment market is segmented into clotrimazole, nystatin, fluconazole, ketoconazole, terbinafine, terconazole and others. In 2021, the fluconazole segment dominated the vulvovaginal candidiasis treatment market with the maximum revenue share. Fungal diseases pose a crucial threat to public health for certain reasons, due to which the market players across the globe are focused on research & development of clinical use of fluconazole.

Regional Outlook

Region wise, the vulvovaginal candidiasis treatment market analyzed across North America, Europe, Asia Pacific and LAMEA. The North America region led the vulvovaginal candidiasis treatment market by generating the maximum revenue share in 2021. The main factor resulting in the region’s dominance in the market is the presence of market players such as Johnson & Johnson Services Inc., Pfizer Inc., and others. Moreover, the regional market is expanding due to the rising prevalence of diabetes in the region, which may lead to increased cases of vulvovaginal candidiasis in the North American nations.

The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Bayer AG, Bristol Myers Squibb Company, Pfizer, Inc., Astellas Pharma, Inc., Mycovia Pharmaceuticals, Inc. (NovaQuest Capital Management,LLC), Basilea Pharmaceutica Ltd., Scynexis, Inc. and Grupo Ferrer Internacional S.A.

Scope of the Study

By Distribution Channel

Retail Pharmacy
Hospital Pharmacy
Online Pharmacy

By Route of Administration

Oral
Intravenous
Topical

By Drug Class

Fluconazole
Clotrimazole
Terconazole
Terbinafine
Nystatin
Ketoconazole
Others

By Geography

North America
US
Canada
Mexico
Rest of North America

Europe
Germany
UK
France
Russia
Spain
Italy
Rest of Europe

Asia Pacific
China
Japan
India
South Korea
Singapore
Malaysia
Rest of Asia Pacific

LAMEA
Brazil
Argentina
UAE
Saudi Arabia
South Africa
Nigeria
Rest of LAMEA

Key Market Players

List of Companies Profiled in the Report:

Bayer AG
Bristol Myers Squibb Company
Pfizer, Inc.
Astellas Pharma, Inc.
Mycovia Pharmaceuticals, Inc. (NovaQuest Capital Management,LLC)
Basilea Pharmaceutica Ltd.
Scynexis, Inc.
Grupo Ferrer Internacional S.A.

Unique Offerings

Exhaustive coverage
The highest number of market tables and figures
Subscription-based model available
Guaranteed best price
Assured post sales research support with 10% customization free

Chapter 1. Market Scope & Methodology

1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Vulvovaginal Candidiasis Treatment Market, by Distribution Channel
1.4.2 Global Vulvovaginal Candidiasis Treatment Market, by Route of Administration
1.4.3 Global Vulvovaginal Candidiasis Treatment Market, by Drug Class
1.4.4 Global Vulvovaginal Candidiasis Treatment Market, by Geography
1.5 Research Methodology

Chapter 2. Market Overview

2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Global Vulvovaginal Candidiasis Treatment Market by Distribution Channel

3.1 Global Retail Pharmacy Market by Region
3.2 Global Hospital Pharmacy Market by Region
3.3 Global Online Pharmacy Market by Region

Chapter 4. Global Vulvovaginal Candidiasis Treatment Market by Route of Administration

4.1 Global Oral Market by Region
4.2 Global Intravenous Market by Region
4.3 Global Topical Market by Region

Chapter 5. Global Vulvovaginal Candidiasis Treatment Market by Drug Class

5.1 Global Fluconazole Market by Region
5.2 Global Clotrimazole Market by Region
5.3 Global Terconazole Market by Region
5.4 Global Terbinafine Market by Region
5.5 Global Nystatin Market by Region
5.6 Global Ketoconazole Market by Region
5.7 Global Others Market by Region

Chapter 6. Global Vulvovaginal Candidiasis Treatment Market by Region

6.1 North America Vulvovaginal Candidiasis Treatment Market
6.1.1 North America Vulvovaginal Candidiasis Treatment Market by Distribution Channel
6.1.1.1 North America Retail Pharmacy Market by Country
6.1.1.2 North America Hospital Pharmacy Market by Country
6.1.1.3 North America Online Pharmacy Market by Country
6.1.2 North America Vulvovaginal Candidiasis Treatment Market by Route of Administration
6.1.2.1 North America Oral Market by Country
6.1.2.2 North America Intravenous Market by Country
6.1.2.3 North America Topical Market by Country
6.1.3 North America Vulvovaginal Candidiasis Treatment Market by Drug Class
6.1.3.1 North America Fluconazole Market by Country
6.1.3.2 North America Clotrimazole Market by Country
6.1.3.3 North America Terconazole Market by Country
6.1.3.4 North America Terbinafine Market by Country
6.1.3.5 North America Nystatin Market by Country
6.1.3.6 North America Ketoconazole Market by Country
6.1.3.7 North America Others Market by Country
6.1.4 North America Vulvovaginal Candidiasis Treatment Market by Country
6.1.4.1 US Vulvovaginal Candidiasis Treatment Market
6.1.4.1.1 US Vulvovaginal Candidiasis Treatment Market by Distribution Channel
6.1.4.1.2 US Vulvovaginal Candidiasis Treatment Market by Route of Administration
6.1.4.1.3 US Vulvovaginal Candidiasis Treatment Market by Drug Class
6.1.4.2 Canada Vulvovaginal Candidiasis Treatment Market
6.1.4.2.1 Canada Vulvovaginal Candidiasis Treatment Market by Distribution Channel
6.1.4.2.2 Canada Vulvovaginal Candidiasis Treatment Market by Route of Administration
6.1.4.2.3 Canada Vulvovaginal Candidiasis Treatment Market by Drug Class
6.1.4.3 Mexico Vulvovaginal Candidiasis Treatment Market
6.1.4.3.1 Mexico Vulvovaginal Candidiasis Treatment Market by Distribution Channel
6.1.4.3.2 Mexico Vulvovaginal Candidiasis Treatment Market by Route of Administration
6.1.4.3.3 Mexico Vulvovaginal Candidiasis Treatment Market by Drug Class
6.1.4.4 Rest of North America Vulvovaginal Candidiasis Treatment Market
6.1.4.4.1 Rest of North America Vulvovaginal Candidiasis Treatment Market by Distribution Channel
6.1.4.4.2 Rest of North America Vulvovaginal Candidiasis Treatment Market by Route of Administration
6.1.4.4.3 Rest of North America Vulvovaginal Candidiasis Treatment Market by Drug Class
6.2 Europe Vulvovaginal Candidiasis Treatment Market
6.2.1 Europe Vulvovaginal Candidiasis Treatment Market by Distribution Channel
6.2.1.1 Europe Retail Pharmacy Market by Country
6.2.1.2 Europe Hospital Pharmacy Market by Country
6.2.1.3 Europe Online Pharmacy Market by Country
6.2.2 Europe Vulvovaginal Candidiasis Treatment Market by Route of Administration
6.2.2.1 Europe Oral Market by Country
6.2.2.2 Europe Intravenous Market by Country
6.2.2.3 Europe Topical Market by Country
6.2.3 Europe Vulvovaginal Candidiasis Treatment Market by Drug Class
6.2.3.1 Europe Fluconazole Market by Country
6.2.3.2 Europe Clotrimazole Market by Country
6.2.3.3 Europe Terconazole Market by Country
6.2.3.4 Europe Terbinafine Market by Country
6.2.3.5 Europe Nystatin Market by Country
6.2.3.6 Europe Ketoconazole Market by Country
6.2.3.7 Europe Others Market by Country
6.2.4 Europe Vulvovaginal Candidiasis Treatment Market by Country
6.2.4.1 Germany Vulvovaginal Candidiasis Treatment Market
6.2.4.1.1 Germany Vulvovaginal Candidiasis Treatment Market by Distribution Channel
6.2.4.1.2 Germany Vulvovaginal Candidiasis Treatment Market by Route of Administration
6.2.4.1.3 Germany Vulvovaginal Candidiasis Treatment Market by Drug Class
6.2.4.2 UK Vulvovaginal Candidiasis Treatment Market
6.2.4.2.1 UK Vulvovaginal Candidiasis Treatment Market by Distribution Channel
6.2.4.2.2 UK Vulvovaginal Candidiasis Treatment Market by Route of Administration
6.2.4.2.3 UK Vulvovaginal Candidiasis Treatment Market by Drug Class
6.2.4.3 France Vulvovaginal Candidiasis Treatment Market
6.2.4.3.1 France Vulvovaginal Candidiasis Treatment Market by Distribution Channel
6.2.4.3.2 France Vulvovaginal Candidiasis Treatment Market by Route of Administration
6.2.4.3.3 France Vulvovaginal Candidiasis Treatment Market by Drug Class
6.2.4.4 Russia Vulvovaginal Candidiasis Treatment Market
6.2.4.4.1 Russia Vulvovaginal Candidiasis Treatment Market by Distribution Channel
6.2.4.4.2 Russia Vulvovaginal Candidiasis Treatment Market by Route of Administration
6.2.4.4.3 Russia Vulvovaginal Candidiasis Treatment Market by Drug Class
6.2.4.5 Spain Vulvovaginal Candidiasis Treatment Market
6.2.4.5.1 Spain Vulvovaginal Candidiasis Treatment Market by Distribution Channel
6.2.4.5.2 Spain Vulvovaginal Candidiasis Treatment Market by Route of Administration
6.2.4.5.3 Spain Vulvovaginal Candidiasis Treatment Market by Drug Class
6.2.4.6 Italy Vulvovaginal Candidiasis Treatment Market
6.2.4.6.1 Italy Vulvovaginal Candidiasis Treatment Market by Distribution Channel
6.2.4.6.2 Italy Vulvovaginal Candidiasis Treatment Market by Route of Administration
6.2.4.6.3 Italy Vulvovaginal Candidiasis Treatment Market by Drug Class
6.2.4.7 Rest of Europe Vulvovaginal Candidiasis Treatment Market
6.2.4.7.1 Rest of Europe Vulvovaginal Candidiasis Treatment Market by Distribution Channel
6.2.4.7.2 Rest of Europe Vulvovaginal Candidiasis Treatment Market by Route of Administration
6.2.4.7.3 Rest of Europe Vulvovaginal Candidiasis Treatment Market by Drug Class
6.3 Asia Pacific Vulvovaginal Candidiasis Treatment Market
6.3.1 Asia Pacific Vulvovaginal Candidiasis Treatment Market by Distribution Channel
6.3.1.1 Asia Pacific Retail Pharmacy Market by Country
6.3.1.2 Asia Pacific Hospital Pharmacy Market by Country
6.3.1.3 Asia Pacific Online Pharmacy Market by Country
6.3.2 Asia Pacific Vulvovaginal Candidiasis Treatment Market by Route of Administration
6.3.2.1 Asia Pacific Oral Market by Country
6.3.2.2 Asia Pacific Intravenous Market by Country
6.3.2.3 Asia Pacific Topical Market by Country
6.3.3 Asia Pacific Vulvovaginal Candidiasis Treatment Market by Drug Class
6.3.3.1 Asia Pacific Fluconazole Market by Country
6.3.3.2 Asia Pacific Clotrimazole Market by Country
6.3.3.3 Asia Pacific Terconazole Market by Country
6.3.3.4 Asia Pacific Terbinafine Market by Country
6.3.3.5 Asia Pacific Nystatin Market by Country
6.3.3.6 Asia Pacific Ketoconazole Market by Country
6.3.3.7 Asia Pacific Others Market by Country
6.3.4 Asia Pacific Vulvovaginal Candidiasis Treatment Market by Country
6.3.4.1 China Vulvovaginal Candidiasis Treatment Market
6.3.4.1.1 China Vulvovaginal Candidiasis Treatment Market by Distribution Channel
6.3.4.1.2 China Vulvovaginal Candidiasis Treatment Market by Route of Administration
6.3.4.1.3 China Vulvovaginal Candidiasis Treatment Market by Drug Class
6.3.4.2 Japan Vulvovaginal Candidiasis Treatment Market
6.3.4.2.1 Japan Vulvovaginal Candidiasis Treatment Market by Distribution Channel
6.3.4.2.2 Japan Vulvovaginal Candidiasis Treatment Market by Route of Administration
6.3.4.2.3 Japan Vulvovaginal Candidiasis Treatment Market by Drug Class
6.3.4.3 India Vulvovaginal Candidiasis Treatment Market
6.3.4.3.1 India Vulvovaginal Candidiasis Treatment Market by Distribution Channel
6.3.4.3.2 India Vulvovaginal Candidiasis Treatment Market by Route of Administration
6.3.4.3.3 India Vulvovaginal Candidiasis Treatment Market by Drug Class
6.3.4.4 South Korea Vulvovaginal Candidiasis Treatment Market
6.3.4.4.1 South Korea Vulvovaginal Candidiasis Treatment Market by Distribution Channel
6.3.4.4.2 South Korea Vulvovaginal Candidiasis Treatment Market by Route of Administration
6.3.4.4.3 South Korea Vulvovaginal Candidiasis Treatment Market by Drug Class
6.3.4.5 Singapore Vulvovaginal Candidiasis Treatment Market
6.3.4.5.1 Singapore Vulvovaginal Candidiasis Treatment Market by Distribution Channel
6.3.4.5.2 Singapore Vulvovaginal Candidiasis Treatment Market by Route of Administration
6.3.4.5.3 Singapore Vulvovaginal Candidiasis Treatment Market by Drug Class
6.3.4.6 Malaysia Vulvovaginal Candidiasis Treatment Market
6.3.4.6.1 Malaysia Vulvovaginal Candidiasis Treatment Market by Distribution Channel
6.3.4.6.2 Malaysia Vulvovaginal Candidiasis Treatment Market by Route of Administration
6.3.4.6.3 Malaysia Vulvovaginal Candidiasis Treatment Market by Drug Class
6.3.4.7 Rest of Asia Pacific Vulvovaginal Candidiasis Treatment Market
6.3.4.7.1 Rest of Asia Pacific Vulvovaginal Candidiasis Treatment Market by Distribution Channel
6.3.4.7.2 Rest of Asia Pacific Vulvovaginal Candidiasis Treatment Market by Route of Administration
6.3.4.7.3 Rest of Asia Pacific Vulvovaginal Candidiasis Treatment Market by Drug Class
6.4 LAMEA Vulvovaginal Candidiasis Treatment Market
6.4.1 LAMEA Vulvovaginal Candidiasis Treatment Market by Distribution Channel
6.4.1.1 LAMEA Retail Pharmacy Market by Country
6.4.1.2 LAMEA Hospital Pharmacy Market by Country
6.4.1.3 LAMEA Online Pharmacy Market by Country
6.4.2 LAMEA Vulvovaginal Candidiasis Treatment Market by Route of Administration
6.4.2.1 LAMEA Oral Market by Country
6.4.2.2 LAMEA Intravenous Market by Country
6.4.2.3 LAMEA Topical Market by Country
6.4.3 LAMEA Vulvovaginal Candidiasis Treatment Market by Drug Class
6.4.3.1 LAMEA Fluconazole Market by Country
6.4.3.2 LAMEA Clotrimazole Market by Country
6.4.3.3 LAMEA Terconazole Market by Country
6.4.3.4 LAMEA Terbinafine Market by Country
6.4.3.5 LAMEA Nystatin Market by Country
6.4.3.6 LAMEA Ketoconazole Market by Country
6.4.3.7 LAMEA Others Market by Country
6.4.4 LAMEA Vulvovaginal Candidiasis Treatment Market by Country
6.4.4.1 Brazil Vulvovaginal Candidiasis Treatment Market
6.4.4.1.1 Brazil Vulvovaginal Candidiasis Treatment Market by Distribution Channel
6.4.4.1.2 Brazil Vulvovaginal Candidiasis Treatment Market by Route of Administration
6.4.4.1.3 Brazil Vulvovaginal Candidiasis Treatment Market by Drug Class
6.4.4.2 Argentina Vulvovaginal Candidiasis Treatment Market
6.4.4.2.1 Argentina Vulvovaginal Candidiasis Treatment Market by Distribution Channel
6.4.4.2.2 Argentina Vulvovaginal Candidiasis Treatment Market by Route of Administration
6.4.4.2.3 Argentina Vulvovaginal Candidiasis Treatment Market by Drug Class
6.4.4.3 UAE Vulvovaginal Candidiasis Treatment Market
6.4.4.3.1 UAE Vulvovaginal Candidiasis Treatment Market by Distribution Channel
6.4.4.3.2 UAE Vulvovaginal Candidiasis Treatment Market by Route of Administration
6.4.4.3.3 UAE Vulvovaginal Candidiasis Treatment Market by Drug Class
6.4.4.4 Saudi Arabia Vulvovaginal Candidiasis Treatment Market
6.4.4.4.1 Saudi Arabia Vulvovaginal Candidiasis Treatment Market by Distribution Channel
6.4.4.4.2 Saudi Arabia Vulvovaginal Candidiasis Treatment Market by Route of Administration
6.4.4.4.3 Saudi Arabia Vulvovaginal Candidiasis Treatment Market by Drug Class
6.4.4.5 South Africa Vulvovaginal Candidiasis Treatment Market
6.4.4.5.1 South Africa Vulvovaginal Candidiasis Treatment Market by Distribution Channel
6.4.4.5.2 South Africa Vulvovaginal Candidiasis Treatment Market by Route of Administration
6.4.4.5.3 South Africa Vulvovaginal Candidiasis Treatment Market by Drug Class
6.4.4.6 Nigeria Vulvovaginal Candidiasis Treatment Market
6.4.4.6.1 Nigeria Vulvovaginal Candidiasis Treatment Market by Distribution Channel
6.4.4.6.2 Nigeria Vulvovaginal Candidiasis Treatment Market by Route of Administration
6.4.4.6.3 Nigeria Vulvovaginal Candidiasis Treatment Market by Drug Class
6.4.4.7 Rest of LAMEA Vulvovaginal Candidiasis Treatment Market
6.4.4.7.1 Rest of LAMEA Vulvovaginal Candidiasis Treatment Market by Distribution Channel
6.4.4.7.2 Rest of LAMEA Vulvovaginal Candidiasis Treatment Market by Route of Administration
6.4.4.7.3 Rest of LAMEA Vulvovaginal Candidiasis Treatment Market by Drug Class

Chapter 7. Company Profiles

7.1 Bayer AG
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.2 Pfizer, Inc.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional & Segmental Analysis
7.2.4 Research & Development Expense
7.3 Bristol Myers Squibb Company
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional Analysis
7.3.4 Research & Development Expenses
7.4 Astellas Pharma, Inc.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expense
7.5 Mycovia Pharmaceuticals, Inc. (NovaQuest Capital Management, LLC)
7.5.1 Company Overview
7.5.2 Recent Strategies and Developments
7.5.2.1 Trials and Approvals
7.6 Basilea Pharmaceutica Ltd.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expenses
7.7 Scynexis, Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Research & Development Expenses
7.7.4 Recent Strategies and Developments
7.7.4.1 Trials and Approvals
7.8 Grupo Ferrer Internacional S.A.
7.8.1 Company Overview

Companies Mentioned

Bayer AG
Bristol Myers Squibb Company
Pfizer, Inc.
Astellas Pharma, Inc.
Mycovia Pharmaceuticals, Inc. (NovaQuest Capital Management,LLC)
Basilea Pharmaceutica Ltd.
Scynexis, Inc.
Grupo Ferrer Internacional S.A.

Methodology

LOADING...

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€3519EUR$3,600USD£2,940GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€4223EUR$4,320USD£3,528GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€5913EUR$6,048USD£4,939GBP

Vulvovaginal Candidiasis Treatment Market Size, Share & Industry Trends Analysis Report By Distribution Channel, By Route of Administration (Oral, Intravenous and Topical), By Drug Class, By Regional Outlook and Forecast, 2022 - 2028

COVID-19 Impact Analysis

Market Growth Factors